Gastrointestinal Therapeutics Market Report by Type, Route of Administration, Application, Distribution Channel, and Region 2024-2032
세계 소화관 치료제 시장 규모는 2023년 465억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 696억 달러에 달해 2024-2032년 사이 4.5%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다.
위장관(GI) 증후군은 소화관 장기의 기능에 영향을 미치는 의학적 질환을 말합니다. 위, 췌장, 소장, 대장, 담낭, 간 등에 영향을 미치며 일반적으로 소화불량, 가슴앓이, 변비, 복부 팽만감이 특징입니다. 일반적으로 사용되는 소화관 치료에는 제산제, 완하제, 완하제, 지사제, 구토제, 항궤양제 등의 처방약과 일반의약품, 내시경 검사, X선 검사, 혈액학적 검사 등이 있습니다. 이러한 치료는 장애를 발견하고 음식물의 영양 흡수를 돕고, 소화를 개선하고, 소화기 계통의 수분 흐름을 조절하고, 위산을 최소화하는 데 도움이 됩니다.
염증성 장질환(IBD) 및 궤양성 대장염과 같은 GI 질환의 유병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 라이프스타일의 변화와 건강에 해로운 식습관으로 인해 전 세계 환자들의 질병 재발 가능성이 높아지고 있습니다. 또한, 이러한 질병에 취약한 노인 인구의 증가는 시장 성장의 원동력이 되고 있습니다. 이 질환의 치료를 위한 혁신적인 바이오시밀러 및 세포 치료제의 개발 등 다양한 기술 발전이 또 다른 성장 촉진요인으로 작용하고 있습니다. 이러한 생물학적 제제는 정맥 또는 피하 주사로 투여되며, 표적 치료를 위해 개별화되어 있습니다. 대중의 건강 인식 증가, 광범위한 R&D 활동, 특히 신흥 경제국에서 의료 인프라의 대폭적인 개선 등 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문들
- 세계 소화관 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 발전할 것인가?
- COVID-19는 세계 소화관 치료제 시장에 어떤 영향을 미쳤을까?
- 주요 지역 시장이란?
- 유형별 시장 분석은?
- 투여 경로별 시장 현황은?
- 용도별 시장 내역은?
- 유통 채널별 시장 현황은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 소화관 치료제 시장의 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 소화관 치료제 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 유형별
제7장 시장 내역 : 투여 경로별
제8장 시장 내역 : 용도별
제9장 시장 내역 : 유통 채널별
제10장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Bayer Aktiengesellschaft
- GlaxoSmithKline Plc
- Janssen Biotech Inc.(Johnson & Johnson)
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceuticals
ksm
The global gastrointestinal therapeutics market size reached US$ 46.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 69.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.
Gastrointestinal (GI) syndrome refers to a medical ailment that affects the functioning of organs in the digestive tract. It impacts the stomach, pancreas, small and large intestines, gall bladder and liver and is usually characterized by indigestion, heartburn, constipation and bloating. Some of the commonly used GI therapeutics include prescription and over-the-counter (OTC) drugs, such as antacids, laxatives, antidiarrheal agents, antiemetics, antiulcer agents, and endoscopic and radiological procedures and hematological tests. These therapeutics assist in the detection of the disorder and absorbing nutrients from the food to improve digestion, regulate water flow in the GI system and minimize gastric acidity.
The increasing prevalence of GI diseases, such as inflammatory bowel disease (IBD) and ulcerative colitis, is one of the key factors driving the growth of the market. Due to changing lifestyle patterns and unhealthy dietary habits, there is an increased probability of disease recurrence among patients across the globe. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Various technological advancements, such as the development of innovative biosimilars and cellular therapies for the treatment of the disorder, are acting as other growth-inducing factors. These biologics are administered through intravenous and subcutaneous injections and are personalized for targeted treatments. Other factors, including rising health consciousness among the masses, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, especially in developing economies, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global gastrointestinal therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, route of administration, application and distribution channel.
Breakup by Type:
Branded
Generic
Breakup by Route of Administration:
Oral
Intravenous
Others
Breakup by Application:
Ulcerative Colitis
Crohn's Disease
GERD
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.
Key Questions Answered in This Report:
- How has the global gastrointestinal therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global gastrointestinal therapeutics market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global gastrointestinal therapeutics market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Gastrointestinal Therapeutics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Branded
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Generic
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Route of Administration
- 7.1 Oral
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intravenous
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Application
- 8.1 Ulcerative Colitis
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Crohn's Disease
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 GERD
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 AbbVie Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca Plc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Bausch Health Companies Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Bayer Aktiengesellschaft
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 GlaxoSmithKline Plc
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Janssen Biotech Inc. (Johnson & Johnson)
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Novo Nordisk A/S
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Takeda Pharmaceuticals
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
